CompletedNot Applicable

Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation

South Korea3,790 participantsStarted 2020-08-25

Plain-language summary

This retrospective cohort study of patients classified by the blood glucose level after reperfusion in liver transplantation repicient. Our object is to investigate whether controlling BG levels within the optimal range during neohepatic phase is associated with a reduction of AKI incidence. Furthermore, severe AKI, chronic kidney disease (CKD), major adverse cardiac event (MACE) and mortality were also investigated.

Who can participate

Age range18 Years – 80 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Living donor liver transplantation recipients Exclusion Criteria: * The exclusion criteria were as follows: recipients under 18 years old, recipients who had undergone deceased donor liver transplantation, recipients who had undergone re-transplantation, recipients with impaired renal function such as CKD or HRS, or those with insufficient data

What they're measuring

incidence of acute kidney injury

Timeframe: within 7 days after surgery

Trial details

NCT IDNCT06320730

SponsorAsan Medical Center

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2020-08-29

View on ClinicalTrials.gov More Acute Kidney Injury trials